文献速递湿疹皮炎与荨麻疹

每周补充维生素D对儿童特应性皮炎严重程度及2型免疫标志物的影响:一项随机对照试验

Effect of weekly vitamin D supplementation on the severity of atopic dermatitis and type 2 immunity biomarkers in children: A randomized controlled trial.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2024-03-14

该随机双盲安慰剂对照试验纳入101例特应性皮炎(AD)患儿,每周口服维生素D3或安慰剂共6周。结果显示维生素D3组25(OH)D显著升高,但SCORAD变化与安慰剂组无差异,2型免疫标志物及金黄色葡萄球菌定植也未见组间差异。

要点

  • 每周口服维生素D3持续6周可显著改善AD患儿维生素D状态。
  • 补充维生素D3未能降低AD严重程度(SCORAD变化与安慰剂无差异)。
  • 嗜酸性粒细胞、总IgE、CCL17/22/27、LL-37及金葡菌定植均无组间差异。

核心结论

  • 在AD患儿中,每周补充维生素D3改善了维生素D状态,但未改变AD严重程度或2型免疫标志物。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,纳入101例AD患儿,随机分配至每周口服维生素D3或安慰剂组,疗程6周。

主要发现

  • 维生素D3组25(OH)D变化显著大于安慰剂组(+43.4 ± 34.5 nmol/L vs. +2.3 ± 21.2 nmol/L,p < 0.001)。
  • 6周时SCORAD变化在维生素D3组与安慰剂组间无差异(-5.3 ± 11.6 vs. -5.5 ± 9.9,p = 0.91)。
  • 嗜酸性粒细胞计数、总IgE、葡萄球菌肠毒素特异性IgE、CCL17、CCL22、CCL27、LL-37及皮损金葡菌定植的变化均无显著组间差异。
  • 维生素D受体基因FokI、ApaI和TaqI单核苷酸多态性未改变受试者对维生素D补充的反应。

关键数值与推荐

  • 基线时57%的患儿存在维生素D缺乏,两组间无差异。
  • 受试者平均年龄6.3 ± 4.0岁,基线SCORAD为32 ± 29。

临床怎么用

  • 对于AD患儿,不应仅以改善AD严重程度为目的而常规补充维生素D。
  • 补充维生素D可用于纠正维生素D缺乏,但需向家长说明其对AD严重程度可能无显著改善。

局限性

  • 原文未报告相关局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vitamin D (VD) deficiency is common among patients with atopic dermatitis (AD) and often associated with severity. However, randomized trials of VD supplementation in AD have had equivocal results, and there is little information regarding the effect of VD supplementation on type 2 immunity in AD patients. OBJECTIVES: To investigate the efficacy of VD supplementation to decrease severity of AD and to alter type 2 immunity biomarkers. METHODS: We performed a randomized, double-blind, placebo-controlled trial. We randomly assigned 101 children with AD to weekly oral vitamin D3 (VD3) or placebo for 6 weeks. The primary outcome was the change in the Severity Scoring of AD (SCORAD). RESULTS: Mean age of subjects was 6.3 ± 4.0 years, and baseline SCORAD was 32 ± 29. At baseline, 57% of children were VD deficient, with no difference between groups. Change in 25(OH)D was significantly greater with VD3 than placebo (+43.4 ± 34.5 nmol/L vs. +2.3 ± 21.2 nmol/L, p < 0.001). SCORAD change at 6 weeks was not different between VD and placebo (-5.3 ± 11.6 vs. -5.5 ± 9.9, p = 0.91). There were no significant between-group differences in change of eosinophil counts, total IgE, Staphylococcal enterotoxin specific IgE, CCL17, CCL22, CCL27, LL-37 or Staphylococcus aureus lesional skin colonization. Vitamin D receptor (VDR) gene single nucleotide polymorphisms FokI, ApaI and TaqI did not modify subjects' response to VD supplementation. CONCLUSIONS: Among children with AD, weekly VD supplementation improved VD status but did not modify AD severity or type 2 immunity biomarkers compared to placebo (ClinicalTrials.gov NCT01996423).

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Borzutzky A, Iturriaga C, Pérez-Mateluna G, et al. Effect of weekly vitamin D supplementation on the severity of atopic dermatitis and type 2 immunity biomarkers in children: A randomized controlled trial. J Eur Acad Dermatol Venereol. 2024. PMID: 38483248. doi:10.1111/jdv.19959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。